Security key
00461U105
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Total 13F shares
- 54,386,842
- Total 13F value
- $67,436,941
- Share change
- -4,066,354
- Put/Call ratio
- 62%
- SEC-reported price per share
- $1.24
- Number of holders
- 93
- Value change
- -$3,788,067
- Number of buys
- 42
- Number of sells
- 64
- Shares outstanding
- 138,752,791
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
93
Top holders
10
ACRS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00461U105
Recent filing periods:
Ownership snapshot
Top reported holders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock Finance, Inc.
Disclosed value leader
BlackRock Finance, Inc.
Comparable rows
15/15
Latest evidence
31 Dec 2023
13F
Lead comparable stake: 4.3%
Showing 1-6 of 15 holder rows.
Quick read
BlackRock Finance, Inc. leads the comparable SEC ownership view at 4.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock Finance, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock Finance, Inc.
4.3%
CITADEL ADVISORS LLC
3.9%
VANGUARD GROUP INC
3.4%
Bain Capital Life Sciences Invest...
2.5%
MILLENNIUM MANAGEMENT LLC
2.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock Finance, Inc. |
13F
Company
|
4.3%
|
$6,201,167
5,905,872 shares
|
— | 31 Dec 2023 |
| CITADEL ADVISORS LLC |
13F
Company
|
3.9%
|
$5,658,229
5,388,789 shares
|
— | 31 Dec 2023 |
| VANGUARD GROUP INC |
13F
Company
|
3.4%
|
$4,958,476
4,722,357 shares
|
— | 31 Dec 2023 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
2.5%
|
$3,675,000
3,500,000 shares
|
— | 31 Dec 2023 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
2.5%
|
$3,653,329
3,479,361 shares
|
— | 31 Dec 2023 |
| Rock Springs Capital Management LP |
13F
Company
|
2.2%
|
$3,148,420
2,998,495 shares
|
— | 31 Dec 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
93
Shares
54,386,842
Rows available
93
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q3 2025 Across Filers
Q3 2025 holders
103
Q1 2024 holders
93
Holder diff
-10
| Investor | Q3 2025 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q3 2025 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend